摘要
目的：探讨促性腺激素释放激素激动剂（gonadotrop in-releasing hormone agonist,GnRHa）对子宫肌瘤及相邻肌层组织细胞凋亡调控基因蛋白Bc l-2的影响。方法：采用免疫组化法测定30例子宫肌瘤患者应用GnRHa（达菲林,3.75 mg/28 d）治疗24个月,末次注射46周后子宫肌瘤及相邻肌层组织细胞凋亡调控基因蛋白Bc l-2的表达水平,并以30例同期手术的子宫肌瘤患者作对照。结果：GnRHa治疗组子宫及肌瘤体积均明显缩小,子宫体积收缩率为（42.77±12.11）%,子宫肌瘤体积收缩率为（37.65±15.20）%。肌瘤细胞内Bc l-2表达水平明显低于对照组（P〈0.01）,肌层组织细胞内Bc l-2表达水平与对照组差异无统计学意义（P〉0.05）。结论：子宫肌瘤细胞内Bc l-2表达水平降低可能是GnRHa缩小子宫肌瘤的重要机制之一。
Objective：To explore the effect of gonadotrophin releasing hormone agonist（GnRHa） on apoptosis regulating gene Bcl-2 in hysteromyoma and adjacent tissues.Methods：30 cases with hysteromyoma were treated with GnRHa（triptorelin,3.75 mg/28 days） for 2～4 months,immunochemical method was used to detect the expression levels of apoptosis regulating gene Bcl-2 in hysteromyoma and adjacent tissues at 4～6 weeks after the last injection,30 cases with hysteromyoma receiving operation at the same time were selected as control group.Results：The volumes of uterus and hysteromyoma in GnRHa group decreased significantly,the shrinking rates of uterus and hysteromyoma were（42.77±12.11）% and（37.65±15.20）%,respectively;the expression level of Bcl-2 in uterine leiomyoma cells of GnRHa group was significantly lower than that in control group（P〈0.01）,there was no significant difference in expression level of Bcl-2 between myometrial tissues of GnRHa group and control group（P〉0.05）.Conclusion：The decrease of Bcl-2 expression in uterine leiomyoma cells may be one of the important mechanisms of hysteromyoma regression after treatment with GnRHa.
出处
《中国妇幼保健》
CAS
北大核心
2010年第34期5101-5103,共3页
Maternal and Child Health Care of China
